Lorbrexen (Lorlatinib)

Patients with ALK-positive non-small-cell lung cancer who have undergone prior treatment and are candidates for Lorbrexen, a third-generation anaplastic lymphoma kinase (ALK) anaplastic lymphoma kinase inhibitor, have shown to benefit from its anticancer properties (NSCLC). 

When compared to crizotinib, it is unknown how effective Lorbrexen is as a first-line treatment for advanced ALK-positive non-small cell lung cancer (NSCLC). 

Individuals with metastatic non-small cell lung cancer who have a particular type of faulty anaplastic lymphoma kinase (ALK) gene are candidates for treatment with the medication Lorbrexen, which is a medicine. Your physician will conduct a test to determine whether or not you have the ALK gene before prescribing you this medicine.

What is the purpose of using this medicine?

Lorbrexen is a drug that is available with a doctor's prescription and is used to treat patients who have non-small cell lung cancer (NSCLC) that is brought on by a flawed copy of the anaplastic lymphoma kinase (ALK) gene and, additionally, that has spread to other areas of your body. 

Patients who have used the medicines Alectinib or ceritinib, or who have taken both the medicine crizotinib and at least one other medicine to treat NSCLC that is caused by the ALK gene, and patients who have had a response to crizotinib.

Their non-small cell lung cancer is not responding to these medicines any longer. It is unknown whether the antidepressant Lorbrexen is both safe and effective for use in youngsters.

The following are some of the most frequently experienced adverse reactions to Lorbrexen:

• you have swelling in your hands, feet, arms, and legs (edema)

• a sensation of numbness and tingling in your joints, or in your arms and legs (peripheral neuropathy)

• a mental block or a state of bewilderment

• difficultly inhaling and exhaling fatigue (fatigue)

• ache in your bones and joints due to weight gain

• alterations in mood, feelings of melancholy or anxiety, diarrhea